H2020Individual fellowship2021–2023

LateCPC · Late-stage C–H bond construction of cyclopropanes to impact drug discovery

Horizon 2020 — Marie Skłodowska-Curie Actions

Duration
2021-03-01 → 2023-02-28
EU contribution
€160,932
Participants
1
Scheme
MSCA-IF

Lines connect the coordinator with its partners.

Results in brief

Late-stage C–H bond construction of cyclopropanes to impact drug discovery

The cyclopropenyl cation (CPC) is the smallest member of the Hückel aromatic systems. This type of aromatic cations with two π-electrons delocalized over three 2p orbitals are known to have considerable thermodynamic stability, despite of their molecular strain. Current synthetic strategies, developed between 1950s and 1980s, rely on multistep sequences to generate a cyclopropene precursor that leads to the CPC upon (pseudo)halide, nitrile or hydride abstraction with strong Lewis acid or Brønsted acid. Those methods show severe limitations in the scope with regards to efficiency and structural diversity. To date, synthetic methods based on a catalytic platform that reaches CPCs in one step are unknown. The evaluation of the CPCs reactivity as electrophiles has been demonstrated principally with hard nucleophiles (RM, M = Li, MgBr, SnBu3, phosphide) and recently, the more stable trisaminocyclopropenyl cations found applications as photoelectrocatalysts, gene delivery promoters or catholytes for nonaqueous redox batteries. However, the full synthetic potential of cyclopropenyl cations has been underdeveloped and underappreciated by the synthetic community, perhaps due to the lack of general one-step processes for their synthesis. CPCs have the potential to be exploited as electrophilic reagents in the regio and stereoselective C–H bond functionalization of aromatic rings and to reach cyclopropenes which are direct precursors of one of the most important saturated carbocycles in drug discovery, the cyclopropane. Novel and stable CPCs as well as C–H bond cyclopropenation are highly innovative and could have direct impact in human health, paving the way for the development of new bioactive compounds containing cyclopropenyl/cyclopropanyl moieties in a straightforward manner from APIs and drug intermediates. Late CPC wants to develop the first general catalytic synthesis of cyclopropenyl cations from readily or commercially available alkynes and exploit them as electrophilic reagents for the first time in late-stage functionlization to impact medicinal chemistry. The specific objectives of this programme include: (1) The development of the first catalytic methodology for the synthesis of a previously elusive family of CPCs. (2) The use of the new CPCs as electrophilic reagents in the regio- and chemoselective couplings with aromatic nucleophiles for the synthesis of valuable cyclopropenes. (3) The development of the first late-stage electrophilic C–H bond cyclopropenation in complex natural products and drug molecules.

Data: CORDIS, © European Union

Project objective

The cyclopropane ring is the 10th most commonly observed core in small-molecule drugs. This is due to the fact that cyclopropanes can positively influence metabolic stability, conformation, pKa, entropy, membrane permeability or pharmacokinetics in drug leads. The cyclopropane ring is often introduced in drug candidates at the early stages of the synthesis, however, the late-stage construction of multi-substituted cyclopropanes using C–H bonds as a functional group has not been developed yet. This concept promise to reach a “cyclopropanated” chemical space not possible by current strategies and that may impact how medicinal chemists will discover cyclopropane-based drugs that address unmet medical needs. LateCPC aims to develop an innovative technology to rapidly construct cyclopropanes from C–H bonds in feedstock and fine aromatic molecules as well as in complex drug molecules. Our approach will rely on the diazo activation of bespoke carbyne sources developed in the host group with metal catalysts, allowing the catalytic generation of metal-carbynoids. A key strength of this conceptually new and multidisciplinary proposal is the introduction of a secondment phase in Novartis (Basel) to explore real-life applications. The ambitious action merges perfectly the expertise of the host in novel C−H functionalization strategies based on the catalytic generation of innovative carbyne equivalents with the strong background of the applicant in metal-catalyzed Tsuji-Trost reactions, thus enhancing two-way transfer of knowledge between the ER and the host group. Successful development of this project will enable the ER to become a leader for the next generation in the field of chemical synthesis and late-stage functionalization techniques. The ER will be exposed to a wide range of cutting-edge chemistry and biomedical sciences in an interdisciplinary and international environment (ICIQ) that will aid the fellow’s competencies and cultivate him as independent researcher.

Original text from CORDIS.

Participants

  • FUNDACIO INSTITUT CATALA D'INVESTIGACIO QUIMICA · TARRAGONACoordinatorSpain

Links

Data: CORDIS, © European Union